Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Daffodil Health Raises $16.3M Series A to Break Health Plans’ Reliance on Percent-of-Savings Middlemen
The New Funding Will Support Daffodil’s Expansion as Its Pricing and Payment Integrity Solution Delivers Seven-Figure Improvements for Payor Partners
Daffodil Health, an AI-powered platform modernizing U.S. health plan administration and claims processing, today announced it has raised $16.3 million, bringing its total funds raised to $20.9M. The series A funding was led by Flare Capital Partners, with participation from LRVHealth and returning investor, Maverick Ventures, alongside key individual investors, including Scott Mingee, former CEO of Equian (acquired by Optum), and Jim Lacy, former President and COO of Collective Medical (acquired by PointClickCare).
The $16.3 million in fresh capital will enable Daffodil to accelerate its product development and expand deployments with health plans and third-party administrators (TPAs) seeking improved price transparency, automated negotiations, and real-time claims support, further displacing legacy vendors. This comes as employers push payors to rein in healthcare costs while delivering more transparency and auditability.
Built around static pricing models and delayed, limited reporting frameworks, legacy claims systems and point solution vendors can’t support the flexible plan designs now gaining traction, such as narrow and tiered networks, reference-based pricing, and dynamic copays. Daffodil addresses this gap by modernizing the claims layer that underpins next-generation, cost-efficient health plans, with a straightforward pricing model that aligns incentives and keeps costs predictable.
These market forces highlight a broader cost crisis across the U.S. healthcare system. Today, healthcare accounts for nearly 20% of the U.S. economy. Unfortunately, the burden of this spending most commonly falls on patients, with 41% of Americans carrying medical debt, 46% of adults skipping necessary care due to cost, and 58% of all U.S. debt collections are tied to medical bills. Daffodil Health has identified administrative inefficiencies as a key driver of the rising cost of healthcare, with more than $1 trillion spent annually on administrative processes.
As an AI-first alternative designed to eliminate this administrative waste, Daffodil enables payers to bring out-of-network (OON) and payment integrity in-house with minimal to no increase in labor costs. The system also allows payors and TPAs to adjust pricing in real-time using transparent benchmarks that withstand regulatory review.
“For too long, health plans have been unable to meaningfully address the healthcare cost crisis because they’ve been forced to pay high fees to middlemen whose incentives often make the problem worse,” said Navin Nagiah, Co-Founder and CEO at Daffodil Health, and former SVP of Products at MultiPlan/Claritev…
Full release here, originally announced February 17th, 2026.
Synchrony Medical Secures $5M Funding to Fuel Commercial Expansion of its At-Home Airway Clearance Device for Chronic Respiratory Disease
Investment Led by Edge Medical Ventures to Accelerate U.S. Commercial Growth and Clinical Adoption of FDA-Cleared LibAirty System
Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty Airway Clearance System, today announced it has closed an oversubscribed $5 million funding round. The investment, led by Edge Medical Ventures with participation from the New Jersey Economic Development Authority (NJEDA), Broadfin Holdings, Consensus Business Group (CBG), and angel investors, will accelerate U.S. commercial expansion, support ongoing clinical research and product development, and broaden patient access to LibAirty.
For millions living with chronic lung conditions, airway clearance is essential to managing symptoms, preventing infections, and slowing disease progression. The LibAirty system delivers this vital therapy through a daily home treatment that has shown the ability to clear twice as much sputum as conventional therapies with enhanced user comfort and satisfaction. Since its commercial launch in late 2025, LibAirty has received an enthusiastic response from both patients and clinicians, demonstrating immediate impact on daily condition management.
“This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health,” said Anat Shani, CEO at Synchrony Medical. “Supported by our exceptional investors and new board members, we’re well-positioned to scale our U.S. market presence, expand our clinical evidence base, and advance product innovation.”
In conjunction with the funding, Synchrony announced the appointment of Kevin Kotler, General Partner at Broadfin Holdings, and Elad Duschak, Strategic Advisor to CBG for Healthcare, to the company’s Board of Directors, strengthening strategic oversight as the company enters its next phase of growth.
“The LibAirty System, with its proven clinical advantage, is poised to disrupt a market with high demand and strong growth,” said Kevin Kotler, General Partner at Broadfin Holdings…
Full release here, originally announced February 18th, 2026.
No comments:
Post a Comment